NCT01565850: D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults |
|
|
| Completed | 2 | 153 | US | D/C/F/TAF, DRV, Prezista®, COBI, Tybost®, GS-9350, FTC/TDF, Truvada®, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo | Gilead Sciences | Acquired Immunodeficiency Syndrome, HIV Infections | 01/13 | 02/14 | | |
